Insys Therapeutics, Inc. Form 4

April 14, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

OMB APPROVAL

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

Common

Stock

04/14/2016

(Print or Type Responses)

1. Name and A MEYER ST	Symbol	2. Issuer Name and Ticker or Trading Symbol Insys Therapeutics, Inc. [INSY]				5. Relationship of Reporting Person(s) to Issuer			
	(First) (I	Middle) 3. Date of (Month/I) CS, 04/14/2	of Earliest Ti Day/Year)				(Check _X_ Director Officer (give below)		Owner r (specify
CHANDLE	(Street) R, AZ 85224 (State)	Filed(Mo	endment, Danth/Day/Year	r)		. .	Person	One Reporting Per Jore than One Re	rson porting
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	e 2A. Deemed	3.	4. Securition(A) or Dis (Instr. 3, 4)	ies Acc sposed	quired of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect
Common Stock	04/14/2016		M	1,500	A	\$ 13.57	19,500	D	

10,500 A

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

M

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

D

\$ 3.63 30,000

Edgar Filing: Insys Therapeutics, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 13.57	04/14/2016		M	1,500	<u>(1)</u>	08/06/2024	Common Stock	1,500	
Stock Option (right to buy)	\$ 3.63	04/14/2016		M	10,500	(2)	05/13/2023	Common Stock	10,500	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
MEYER STEVEN J C/O INSYS THERAPEUTICS, INC. 444 SOUTH ELLIS STREET CHANDLER, AZ 85224	X					

Signatures

/s/Darryl Baker, Attorney-in-Fact 04/15/2016

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) One third of the shares subject to the option shall vest on August 7, 2015 and the remainder shall vest in 24 equal monthly installments thereafter until fully vested and exercisable on August 7, 2017.
- (2) One third of the shares subject to the option shall vest on May 14, 2014 and the remainder shall vest in 24 equal monthly installments thereafter until fully vested and exercisable on May 14, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2